GE Partners with Takeda to Develop Therapeutic Drugs for Liver Disease
GE Healthcare and Takeda Pharmaceutical Company announced an alliance to develop therapeutic drugs in the field of hepatic fibrosis to treat various liver diseases.
GE Healthcare announced on Nov. 11, 2014 an alliance agreement with Takeda Pharmaceutical to research and develop therapeutic drugs to target liver diseases. According to the alliance agreement, GE will provide Takeda with its diagnostic imaging technology to help develop diagnostic technologies and therapeutic drugs for liver diseases.
The collaboration will focus on hepatic fibrosis. The diagnosis of hepatic fibrosis is mostly conducted by a liver biopsy. With this partnership, however, Takeda will be able to use GE’s MR elastography, an MRI used to generate images depicting the elasticity of the body’s internal tissues based on pulses administered externally, to measure the relative stiffness of the liver tissue in a non-invasive manner.
Source: GE Healthcare
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
